AYAL Capital Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

AYAL Capital Advisors’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-20,000	Closed	-$6.06M	–	58
2025 Q4	$6.06M	Buy	20,000 +2,500	+14%	+$780K	2.11%	12
2025 Q3	$4.91M	Buy	+17,500	New	+$4.76M	1.93%	20
2025 Q1	–	Sell	-13,600	Closed	-$4.47M	–	45
2024 Q4	$4.47M	Buy	+13,600	New	+$4.62M	1.15%	29

Other funds holding BIO

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AYAL Capital Advisors's BIO Position: Q1 2026 in Review

AYAL Capital Advisors sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2026, closing a stake of 20,000 shares — an estimated $6.06M sold.

AYAL Capital Advisors first reported a position in BIO in Q4 2024 and held it in 3 quarters. The position peaked at $6.06M in Q4 2025. 391 funds tracked by Wall St. Rank hold BIO as of Q1 2026.

AYAL Capital Advisors reported no remaining Bio-Rad Laboratories Class A position as of Q1 2026 after selling out during the quarter.
AYAL Capital Advisors sold 20,000 Bio-Rad Laboratories Class A shares in Q1 2026, an estimated $6.06M.
AYAL Capital Advisors first reported a position in Bio-Rad Laboratories Class A in Q4 2024 and held it in 3 quarters.
AYAL Capital Advisors's Bio-Rad Laboratories Class A position peaked at $6.06M in Q4 2025.
391 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2026.

Based on AYAL Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.